Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales Market Outlook

The global market for Chemotherapy Induced Nausea and Vomiting (CINV) drugs is poised to reach an impressive valuation of approximately USD 6.5 billion by 2035, with a robust compound annual growth rate (CAGR) of around 7.5% during the forecast period spanning from 2025 to 2035. This growth can be attributed to the increasing prevalence of cancer, resulting in a higher demand for effective CINV management. Furthermore, advancements in drug development and the introduction of novel therapies aim to improve patient quality of life, thereby propelling market expansion. The rising awareness regarding the adverse effects of chemotherapy, coupled with the growing number of treatment options available, provides a substantial boost to the market. Additionally, ongoing research and development initiatives focused on enhancing the efficacy of CINV medications are expected to further drive the market growth as healthcare providers strive to ensure optimal therapeutic outcomes for cancer patients.

Growth Factor of the Market

The growth of the CINV drugs market is significantly influenced by various factors, including the increasing incidence of cancer globally. According to the World Health Organization (WHO), the number of cancer cases is expected to rise, leading to a higher demand for effective supportive care treatments, including anti-nausea medications. Furthermore, advancements in chemotherapy regimens that are more aggressive in nature tend to exacerbate nausea and vomiting, necessitating stronger management strategies. Additionally, the development of innovative formulations, such as long-acting injectable therapies and orally dissolving tablets, is attracting greater attention from oncologists and patients alike, thereby expanding treatment options and improving compliance. Moreover, the strategic partnerships and collaborations among pharmaceutical companies to enhance drug portfolios and share resources for research initiatives play a vital role in shaping market dynamics. Lastly, increasing investments in healthcare infrastructure, especially in emerging economies, are expected to enhance accessibility to CINV drugs and contribute to the market's growth trajectory.

Key Highlights of the Market

• The CINV drugs market is witnessing a surge in demand due to rising cancer cases globally.
• Innovative product developments, such as long-acting formulations, are expanding treatment options.
• Strategic collaborations and partnerships amongst major pharmaceutical players are on the rise.
• Increasing awareness around chemotherapy side effects is boosting market growth.
• Emerging economies are experiencing improved access to CINV treatments, driving market expansion.

By Product Type

5-HT3 Antagonists:

5-HT3 antagonists, such as Ondansetron, are a cornerstone of CINV management due to their proven efficacy in reducing both acute and delayed nausea and vomiting associated with chemotherapy. Their mechanism of action involves blocking serotonin receptors, which play a crucial role in the vomiting reflex. The demand for 5-HT3 antagonists remains strong as they are often the first-line treatment prescribed to patients undergoing chemotherapy. Several clinical trials and studies have highlighted their effectiveness, thereby enhancing their market penetration. Furthermore, the development of generic versions has made these medications more affordable and accessible, contributing to their widespread use. As a result, the market for 5-HT3 antagonists is expected to maintain a significant share, driven by continual updates in treatment guidelines and the growing focus on symptom management in cancer care.

NK1 Receptor Antagonists:

NK1 receptor antagonists, including Aprepitant, are gaining traction in the CINV drugs market due to their ability to manage delayed nausea and vomiting, which can be particularly debilitating for patients undergoing chemotherapy. These medications work by blocking the action of substance P, a neuropeptide associated with the vomiting reflex. As oncology treatment regimens evolve and include more potent chemotherapeutics, the use of NK1 receptor antagonists is becoming more prevalent as part of combination therapy with 5-HT3 antagonists and corticosteroids. The increasing focus on comprehensive nausea management is propelling the growth of this segment. Moreover, ongoing research into the combination of NK1 receptor antagonists with other agents may further expand their use and market share in the coming years.

Corticosteroids:

Corticosteroids such as Dexamethasone are widely utilized in conjunction with other antiemetic agents to effectively control nausea and vomiting in cancer patients. They work by inhibiting inflammation and can enhance the effectiveness of other antiemetics, making them a valuable component of CINV management. The dual role of corticosteroids in not only alleviating CINV but also in managing other chemotherapy side effects contributes to their sustained demand in the market. The segment is further bolstered by the fact that these medications are available as generics, which helps improve affordability and accessibility for patients. Increased adoption of corticosteroids in treatment protocols and their proven efficacy will continue to support their market growth in the years ahead.

Benzodiazepines:

Benzodiazepines, including Lorazepam, are primarily used for their anxiolytic properties but also play a role in managing anticipatory nausea and vomiting that can occur in patients undergoing chemotherapy. These medications help alleviate anxiety related to chemotherapy administration, thereby indirectly reducing the incidence of nausea and vomiting. The growing recognition of the psychological aspects of cancer treatment, including anxiety management, has led to an increased utilization of benzodiazepines in CINV protocols. As oncology practices emphasize holistic patient care, the demand for benzodiazepines is expected to rise, further solidifying their position within the CINV drugs market.

Cannabinoids:

Cannabinoids, with Cannabidiol being the most notable, have emerged as alternative therapies in managing CINV, particularly for patients who may not respond well to traditional antiemetics. These compounds interact with the endocannabinoid system, providing relief from nausea and vomiting through different pathways than classical antiemetics. The growing acceptance of medical cannabis and increasing clinical evidence supporting its efficacy in managing chemotherapy-induced symptoms have contributed to the rise of this segment. As regulations around cannabis use continue to evolve and more states legalize medical cannabis, the cannabinoid market is expected to expand, offering patients additional options for managing CINV.

By Application

Chemotherapy-induced Nausea:

Chemotherapy-induced nausea is a distressing side effect that affects a significant number of patients undergoing cancer treatment. The market for drugs targeting this condition is robust due to the high prevalence of nausea during chemotherapy cycles. Anti-nausea medications, particularly 5-HT3 antagonists and NK1 receptor antagonists, are commonly prescribed to combat this issue. The need for effective nausea management has garnered attention from healthcare providers, leading to an increased emphasis on symptom control in oncology. Consequently, the application of antiemetic drugs specifically for chemotherapy-induced nausea is expected to grow, driven by ongoing research and the development of newer, more effective formulations.

Chemotherapy-induced Vomiting:

Chemotherapy-induced vomiting represents another critical concern for patients undergoing cancer treatment, often leading to poor patient compliance and decreased quality of life. The market addressing chemotherapy-induced vomiting is experiencing significant growth due to the availability of various effective medications that can prevent and manage this side effect. As healthcare providers strive to optimize treatment regimens and improve patient outcomes, the emphasis on controlling vomiting is paramount. The application of combinations of antiemetic agents, including 5-HT3 antagonists and NK1 receptor antagonists, is a common strategy employed to mitigate this condition. Overall, the growing focus on managing vomiting adds substantial value to the CINV drugs market.

By Distribution Channel

Hospitals:

Hospitals constitute a significant distribution channel for CINV drugs as they are primary healthcare settings providing chemotherapy treatments. Inpatient and outpatient chemotherapy services require immediate access to antiemetic medications, making hospitals a crucial factor in the CINV drugs market. The presence of oncology specialists within hospitals facilitates the administration of tailored treatments for patients experiencing nausea and vomiting associated with chemotherapy. Moreover, hospitals often have pharmacy departments that can dispense a wide range of antiemetic medications, including those that are less commonly prescribed. The increasing number of cancer treatment centers and a rise in hospital admissions are expected to further bolster the growth of this distribution channel.

Retail Pharmacies:

Retail pharmacies play a significant role in the distribution of CINV drugs, providing patients with access to medications after their chemotherapy sessions. Patients often seek antiemetic drugs at retail pharmacies to manage their symptoms at home. The availability of both prescription and over-the-counter medications at these locations makes retail pharmacies a convenient option for patients. Furthermore, the growing trend of patient-centered care and the rise of specialized oncology pharmacies within the retail sector enhance the accessibility of CINV medications. As more patients seek to manage their symptoms outside of the hospital environment, the retail pharmacy market for CINV drugs is poised for continued growth.

Online Pharmacies:

The rise of e-commerce has significantly impacted the distribution of CINV drugs, with online pharmacies gaining popularity among patients seeking convenience and privacy. Online platforms offer a discreet option for individuals to purchase their medications, particularly for those who may feel uncomfortable discussing their symptoms in-person. The recent global shift towards telehealth and online consultations has further accelerated the adoption of online pharmacies for obtaining prescriptions for CINV medications. Additionally, the increased prevalence of home delivery options enhances accessibility for patients who may face mobility challenges or live in remote areas. As online pharmacies continue to expand their services and improve user experience, their market share within the CINV drugs sector is expected to rise significantly.

By Ingredient Type

Ondansetron:

Ondansetron is a widely used 5-HT3 antagonist that has become a standard treatment for managing CINV due to its efficacy in preventing nausea and vomiting. Its popularity stems from a robust clinical history demonstrating its effectiveness in both acute and delayed CINV, making it a preferred choice among oncologists. The availability of intravenous and oral formulations allows for flexible administration routes suitable for various patient needs. Furthermore, the transition to generic versions has significantly reduced the cost barriers, increasing its accessibility. As a result, Ondansetron's established track record and wide availability will likely support its dominance in the CINV drugs market.

Aprepitant:

Aprepitant, an NK1 receptor antagonist, is gaining traction in the CINV drugs market due to its unique mechanism of action in managing delayed nausea and vomiting. Aprepitant is often used in combination with 5-HT3 antagonists and corticosteroids to enhance overall antiemetic efficacy. The drug's ability to effectively control symptoms associated with highly emetogenic chemotherapy regimens has made it a key component in CINV treatment protocols. As healthcare providers increasingly adopt multi-drug regimens to improve patient outcomes, the demand for Aprepitant is anticipated to grow consistently. Additionally, ongoing clinical trials may further validate its use in various chemotherapy settings, contributing to its market expansion.

Dexamethasone:

Dexamethasone, a corticosteroid, is frequently utilized in CINV management due to its anti-inflammatory properties and its role in enhancing the effectiveness of other antiemetic agents. The ability of Dexamethasone to address both nausea and vomiting makes it an integral part of combination therapy for patients undergoing chemotherapy. Its affordability and availability in various formulations, including oral tablets and injections, enhance its appeal among healthcare providers. As treatment guidelines increasingly emphasize the importance of managing CINV in conjunction with chemotherapy regimens, Dexamethasone's sustained demand will contribute positively to its market segment.

Lorazepam:

Lorazepam, a benzodiazepine, is primarily used for its anxiolytic properties but plays a valuable role in managing anticipatory nausea and vomiting associated with chemotherapy. It is particularly beneficial for patients who experience anxiety before treatment, helping to improve their overall experience during the chemotherapy process. The growing emphasis on addressing the psychological aspects of cancer care has led to an increase in Lorazepam's application within CINV protocols. The drug's ability to improve patient comfort levels during chemotherapy is driving its demand, and it is increasingly recognized as an important component of comprehensive CINV management strategies.

Cannabidiol:

Cannabidiol, a cannabinoid derived from the cannabis plant, is emerging as a novel therapy for managing CINV, particularly for patients who do not respond adequately to traditional antiemetics. The growing acceptance of medical cannabis has paved the way for research exploring its efficacy in alleviating nausea and vomiting in cancer patients. Cannabidiol has shown promise in preliminary studies, and its unique mechanism of action offers a different approach to symptom management. As regulations surrounding cannabis-based therapies continue to evolve and further clinical studies validate its effectiveness, the cannabinoid segment is expected to grow within the CINV drugs market, offering patients additional options for symptom relief.

By Region

North America is projected to hold the largest share of the CINV drugs market, primarily driven by the high prevalence of cancer and the advanced healthcare infrastructure in the region. The United States, being a major player, witnesses a significant number of cancer diagnoses, leading to increased demand for effective CINV management. Additionally, the presence of major pharmaceutical companies and ongoing research initiatives contribute to a vibrant market landscape. The North American CINV drugs market is expected to grow at a CAGR of around 8% during the forecast period, driven by the continual development of new therapies and the increasing emphasis on patient-centered care.

Europe is another vital region in the CINV drugs market, characterized by a growing population of cancer patients and advancements in healthcare policies. The increasing focus on improving patient outcomes and quality of life is driving the adoption of effective antiemetics across various European countries. The European market benefits from a well-established healthcare system that promotes the use of evidence-based therapies, contributing to the growth of the CINV drugs segment. As awareness surrounding the management of chemotherapy side effects rises, the market for CINV drugs in Europe is expected to witness significant growth, aligning with global trends.

Opportunities

The CINV drugs market is poised to capitalize on numerous opportunities that could further enhance its growth trajectory. One significant opportunity lies in the ongoing advancements in drug formulations and delivery methods that aim to improve patient adherence and minimize side effects. Pharmaceutical companies are increasingly focusing on developing long-acting injectable therapies and oral formulations that can improve patient convenience and compliance. Moreover, the growing trend of personalized medicine presents an opportunity for developing tailored antiemetic therapies based on individual patient profiles, including genetic markers that influence drug efficacy. This could lead to improved treatment outcomes and a more patient-centered approach to CINV management, ultimately expanding market opportunities for innovative products.

Another promising opportunity is the potential for expanding access to CINV drugs in emerging economies. As healthcare infrastructure improves and access to cancer treatment increases in regions such as Asia Pacific and Latin America, the demand for CINV management will rise correspondingly. Pharmaceutical companies that strategically position themselves in these emerging markets can tap into a growing patient base seeking effective antiemetic therapies. Additionally, collaborating with local healthcare providers and establishing distribution networks can facilitate market entry and enhance brand visibility. This focus on geographical expansion, combined with effective marketing strategies, could be key drivers for sustained growth in the CINV drugs market.

Threats

While the CINV drugs market presents numerous growth opportunities, it is not without its challenges. One significant threat is the increasing competition from alternative therapies and natural remedies for managing chemotherapy-induced nausea and vomiting. The rising interest in holistic and integrative approaches to cancer care has led some patients to seek out non-pharmaceutical options, potentially impacting the market share of traditional antiemetic medications. This shift in patient preferences may necessitate pharmaceutical companies to adapt their strategies and invest in research to demonstrate the superiority of their products over emerging alternatives. Additionally, any changes in regulatory policies regarding antiemetic drugs or the introduction of pricing controls could pose significant challenges to market growth and profitability.

Another potential restraining factor is the cost associated with some of the newer CINV medications. While many effective antiemetic therapies are available, not all patients have equal access, especially in regions with limited healthcare coverage and high out-of-pocket expenses. Inequalities in access to effective treatment can hinder patient outcomes and contribute to poor compliance with prescribed therapies. To address this, pharmaceutical companies must emphasize cost-effective solutions, such as providing patient assistance programs and working with healthcare systems to ensure greater availability of essential CINV drugs. Overcoming these barriers is crucial for maximizing market potential and ensuring that patients receive the care they need.

Competitor Outlook

• Roche
• Merck & Co.
• GSK (GlaxoSmithKline)
• Amgen
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Helsinn Healthcare
• Novartis AG
• Boehringer Ingelheim
• Mylan N.V.
• Hikma Pharmaceuticals
• Eisai Co., Ltd.
• Sun Pharmaceutical Industries
• Alchemia Limited
• Insys Therapeutics

The competitive landscape of the CINV drugs market is characterized by the presence of several prominent players engaged in the development, manufacturing, and distribution of antiemetic medications. These companies employ various strategies to maintain their competitive edge, including extensive research and development activities aimed at introducing novel therapies that offer enhanced efficacy and safety profiles. In recent years, the market has witnessed a trend towards consolidation, with several major players acquiring smaller companies to expand their product portfolios and strengthen their market presence. This trend, combined with the increasing focus on personalized medicine, is reshaping the competitive dynamics of the CINV drugs market.

Prominent companies such as Roche and Merck & Co. have established a strong foothold in the CINV drugs market through their extensive product offerings, innovative research, and commitment to improving patient outcomes. Roche's investment in oncology research has led to the successful development of several antiemetic therapies that are widely used in clinical settings. Similarly, Merck has been at the forefront of developing combination therapies that target both acute and delayed CINV, thereby enhancing treatment efficacy. These companies are continuously seeking to invest in clinical trials and collaborations to explore new indications for existing drugs while simultaneously working on novel drug candidates.

Additionally, companies like Teva Pharmaceutical Industries and Pfizer Inc. have made significant strides in the CINV drugs market by leveraging their expertise in generic drug development. The availability of generic versions of well-established antiemetic medications has made treatment more affordable for patients, thereby expanding market access. These companies are also focusing on strategic partnerships and collaborations with healthcare providers and research institutions to gather real-world evidence on the effectiveness of their products, further cementing their position in the market. Overall, the competitive landscape is evolving rapidly, with companies striving to innovate and meet the growing demand for effective CINV therapies.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Mylan N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Merck & Co.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Eisai Co., Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Alchemia Limited
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Helsinn Healthcare
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Insys Therapeutics
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GSK (GlaxoSmithKline)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hikma Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales Market, By Application
    • 6.1.1 Chemotherapy-induced Nausea
    • 6.1.2 Chemotherapy-induced Vomiting
  • 6.2 Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales Market, By Product Type
    • 6.2.1 5-HT3 Antagonists
    • 6.2.2 NK1 Receptor Antagonists
    • 6.2.3 Corticosteroids
    • 6.2.4 Benzodiazepines
    • 6.2.5 Cannabinoids
  • 6.3 Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales Market, By Ingredient Type
    • 6.3.1 Ondansetron
    • 6.3.2 Aprepitant
    • 6.3.3 Dexamethasone
    • 6.3.4 Lorazepam
    • 6.3.5 Cannabidiol
  • 6.4 Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Sales market is categorized based on

By Product Type

• 5-HT3 Antagonists
• NK1 Receptor Antagonists
• Corticosteroids
• Benzodiazepines
• Cannabinoids

By Application

• Chemotherapy-induced Nausea
• Chemotherapy-induced Vomiting

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Ondansetron
• Aprepitant
• Dexamethasone
• Lorazepam
• Cannabidiol

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche
• Merck & Co.
• GSK (GlaxoSmithKline)
• Amgen
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Helsinn Healthcare
• Novartis AG
• Boehringer Ingelheim
• Mylan N.V.
• Hikma Pharmaceuticals
• Eisai Co., Ltd.
• Sun Pharmaceutical Industries
• Alchemia Limited
• Insys Therapeutics